Browse STX19

Summary
SymbolSTX19
Namesyntaxin 19
Aliases MGC21382; Syntaxin-19
Chromosomal Location3q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Peripheral membrane protein Cytoplasm
Domain PF00804 Syntaxin
Function

Plays a role in endosomal trafficking of the epidermal growth factor receptor (EGFR).

> Gene Ontology
 
Biological Process GO:0001505 regulation of neurotransmitter levels
GO:0006836 neurotransmitter transport
GO:0006887 exocytosis
GO:0006906 vesicle fusion
GO:0007269 neurotransmitter secretion
GO:0016050 vesicle organization
GO:0016079 synaptic vesicle exocytosis
GO:0017156 calcium ion regulated exocytosis
GO:0022406 membrane docking
GO:0023061 signal release
GO:0031629 synaptic vesicle fusion to presynaptic active zone membrane
GO:0044801 single-organism membrane fusion
GO:0045026 plasma membrane fusion
GO:0045055 regulated exocytosis
GO:0048278 vesicle docking
GO:0048284 organelle fusion
GO:0048489 synaptic vesicle transport
GO:0051640 organelle localization
GO:0051648 vesicle localization
GO:0051650 establishment of vesicle localization
GO:0051656 establishment of organelle localization
GO:0061025 membrane fusion
GO:0090174 organelle membrane fusion
GO:0097479 synaptic vesicle localization
GO:0097480 establishment of synaptic vesicle localization
GO:0099003 vesicle-mediated transport in synapse
GO:0099500 vesicle fusion to plasma membrane
GO:0099504 synaptic vesicle cycle
GO:0099531 presynaptic process involved in chemical synaptic transmission
GO:0099643 signal release from synapse
Molecular Function GO:0000149 SNARE binding
GO:0005484 SNAP receptor activity
Cellular Component GO:0008021 synaptic vesicle
GO:0030133 transport vesicle
GO:0031201 SNARE complex
GO:0070382 exocytic vesicle
GO:0098793 presynapse
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04130 SNARE interactions in vesicular transport
Reactome -
Summary
SymbolSTX19
Namesyntaxin 19
Aliases MGC21382; Syntaxin-19
Chromosomal Location3q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between STX19 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSTX19
Namesyntaxin 19
Aliases MGC21382; Syntaxin-19
Chromosomal Location3q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of STX19 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSTX19
Namesyntaxin 19
Aliases MGC21382; Syntaxin-19
Chromosomal Location3q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of STX19 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3180.309
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0510.934
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5910.257
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2640.546
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.010.992
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6050.667
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.6230.0337
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.5740.277
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.7610.247
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1580.727
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1580.813
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0970.752
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of STX19 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSTX19
Namesyntaxin 19
Aliases MGC21382; Syntaxin-19
Chromosomal Location3q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of STX19. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSTX19
Namesyntaxin 19
Aliases MGC21382; Syntaxin-19
Chromosomal Location3q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of STX19. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by STX19.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSTX19
Namesyntaxin 19
Aliases MGC21382; Syntaxin-19
Chromosomal Location3q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of STX19. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSTX19
Namesyntaxin 19
Aliases MGC21382; Syntaxin-19
Chromosomal Location3q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of STX19 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSTX19
Namesyntaxin 19
Aliases MGC21382; Syntaxin-19
Chromosomal Location3q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between STX19 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSTX19
Namesyntaxin 19
Aliases MGC21382; Syntaxin-19
Chromosomal Location3q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting STX19 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.